Eli Lilly targets alleged black market sales of its experimental GLP-1 drug

Дата публикации: 12-08-2026 16:19:16

Eli Lilly is suing six entities that it alleges are selling black market versions of its experimental weight-loss drug retatrutide.  Lilly's lawsuits target U.S. entities selling illegal retatrutide products, including compounding pharmacies, medical spas and online sellers that sell retatrutide as a weight-loss "hack." Those entities falsely claim their drugs are for “research-use only” when...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Eli Lilly takes aim at illicit market for its experimental weight-loss drug	0	13.99	12-08-2026
2	Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising	0	7	21-07-2026
3	Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads	0	7	21-07-2026
4	Роспотребнадзор прекратил торговлю средством для похудения Retatrutide, у которого нет сертификата безопасности	-2	7	14-07-2026
5	GLP-1 Users Are Reshaping Retail With Every Pound They Shed	0	14.13	20-07-2026
6	The FDA Should Not Allow Untested Peptides to Be Added Into Patients’ Medications	0	10.69	22-07-2026
7	New GLP-1 pill delivers up to 12% weight loss in 36 weeks	0	11.64	10-08-2026
8	Interceptan en Donostia un envío de Retatrutide desde Reino Unido, un medicamento contra la obesidad y la diabetes no autorizado	0	5	03-07-2026
9	Compounded GLP-1 drugs creating concern among doctors and FDA	0	6.75	27-07-2026
10	Weight loss drugs may literally be saving people's arms and legs	5	7	06-07-2026

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.2. Источник: thehill.com.